We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00720876
Recruitment Status : Completed
First Posted : July 23, 2008
Last Update Posted : June 12, 2017
National Cancer Institute (NCI)
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
City of Hope Medical Center